Market Research

Cardiovascular Drugs Market [Indication: Hypertension, Hyperlipidemia, Coronary Artery Disease, Peripheral Artery Disease, Arrhythmia, and Others; Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy] – Global Industry Analysis, S

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 241 Pages Transparency Market Research Pvt. Ltd. December, 2023 TNPR18480107
Best Price Guarantee
Price from $5,795
Length 241 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date December, 2023
SKU TNPR18480107

Cardiovascular Drugs Market [Indication: Hypertension, Hyperlipidemia, Coronary Artery Disease, Peripheral Artery Disease, Arrhythmia, and Others; Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy] – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Cardiovascular Drugs Market – Scope of Report

TMR’s report on the global Parkinson's disease therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Parkinson's disease therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Parkinson's disease therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Parkinson's disease therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Parkinson's disease therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Parkinson's disease therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Parkinson's disease therapeutics market.

The report delves into the competitive landscape of the global Parkinson's disease therapeutics market. Key players operating in the global Parkinson's disease therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Parkinson's disease therapeutics market profiled in this report.

Key Questions Answered in Global Parkinson's disease therapeutics Market Report
  • What is the sales/revenue generated by Parkinson's disease therapeutics across all regions during the forecast period?
  • What are the opportunities in the global Parkinson's disease therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?Cardiovascular Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global Parkinson's disease therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Parkinson's disease therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Parkinson's disease therapeutics market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiovascular Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiovascular Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Cardiovascular Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Renin-Angiotensin System Blockers
6.3.1.1. ACE Inhibitors
6.3.1.2. Angiotensin Receptor Blockers
6.3.2. Beta Blockers
6.3.3. Diuretics
6.3.4. Anti-Clotting Agents
6.3.4.1. Anti-Coagulants
6.3.4.2. Platelet Aggregation Inhibitors
6.3.5. Antihyperlipidemics
6.3.6. Other Antihypertensive
6.3.7. Calcium Channel Blockers
6.3.8. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Cardiovascular Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Hypertension
7.3.2. Hyperlipidemia
7.3.3. Coronary Artery Disease
7.3.4. Peripheral Artery Disease
7.3.5. Arrhythmia
7.3.6. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Cardiovascular Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Cardiovascular Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cardiovascular Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Renin-Angiotensin System Blockers
10.3.1.1. ACE Inhibitors
10.3.1.2. Angiotensin Receptor Blockers
10.3.2. Beta Blockers
10.3.3. Diuretics
10.3.4. Anti-Clotting Agents
10.3.4.1. Anti-Coagulants
10.3.4.2. Platelet Aggregation Inhibitors
10.3.5. Antihyperlipidemics
10.3.6. Other Antihypertensive
10.3.7. Calcium Channel Blockers
10.3.8. Others
10.4. Market Value Forecast, by Indication, 2017–2031
10.4.1. Hypertension
10.4.2. Hyperlipidemia
10.4.3. Coronary Artery Disease
10.4.4. Peripheral Artery Disease
10.4.5. Arrhythmia
10.4.6. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Cardiovascular Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Renin-Angiotensin System Blockers
11.3.1.1. ACE Inhibitors
11.3.1.2. Angiotensin Receptor Blockers
11.3.2. Beta Blockers
11.3.3. Diuretics
11.3.4. Anti-Clotting Agents
11.3.4.1. Anti-Coagulants
11.3.4.2. Platelet Aggregation Inhibitors
11.3.5. Antihyperlipidemics
11.3.6. Other Antihypertensive
11.3.7. Calcium Channel Blockers
11.3.8. Others
11.4. Market Value Forecast, by Indication, 2017–2031
11.4.1. Hypertension
11.4.2. Hyperlipidemia
11.4.3. Coronary Artery Disease
11.4.4. Peripheral Artery Disease
11.4.5. Arrhythmia
11.4.6. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Cardiovascular Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Renin-Angiotensin System Blockers
12.3.1.1. ACE Inhibitors
12.3.1.2. Angiotensin Receptor Blockers
12.3.2. Beta Blockers
12.3.3. Diuretics
12.3.4. Anti-Clotting Agents
12.3.4.1. Anti-Coagulants
12.3.4.2. Platelet Aggregation Inhibitors
12.3.5. Antihyperlipidemics
12.3.6. Other Antihypertensive
12.3.7. Calcium Channel Blockers
12.3.8. Others
12.4. Market Value Forecast, by Indication, 2017–2031
12.4.1. Hypertension
12.4.2. Hyperlipidemia
12.4.3. Coronary Artery Disease
12.4.4. Peripheral Artery Disease
12.4.5. Arrhythmia
12.4.6. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacy
12.5.2. Retail Pharmacy
12.5.3. Online Pharmacy
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Cardiovascular Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Renin-Angiotensin System Blockers
13.3.1.1. ACE Inhibitors
13.3.1.2. Angiotensin Receptor Blockers
13.3.2. Beta Blockers
13.3.3. Diuretics
13.3.4. Anti-Clotting Agents
13.3.4.1. Anti-Coagulants
13.3.4.2. Platelet Aggregation Inhibitors
13.3.5. Antihyperlipidemics
13.3.6. Other Antihypertensive
13.3.7. Calcium Channel Blockers
13.3.8. Others
13.4. Market Value Forecast, by Indication, 2017–2031
13.4.1.1. Hypertension
13.4.1.2. Hyperlipidemia
13.4.1.3. Coronary Artery Disease
13.4.1.4. Peripheral Artery Disease
13.4.1.5. Arrhythmia
13.4.1.6. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacy
13.5.2. Retail Pharmacy
13.5.3. Online Pharmacy
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Cardiovascular Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Renin-Angiotensin System Blockers
14.3.1.1. ACE Inhibitors
14.3.1.2. Angiotensin Receptor Blockers
14.3.2. Beta Blockers
14.3.3. Diuretics
14.3.4. Anti-Clotting Agents
14.3.4.1. Anti-Coagulants
14.3.4.2. Platelet Aggregation Inhibitors
14.3.5. Antihyperlipidemics
14.3.6. Other Antihypertensive
14.3.7. Calcium Channel Blockers
14.3.8. Others
14.4. Market Value Forecast, by Indication, 2017–2031
14.4.1. Hypertension
14.4.2. Hyperlipidemia
14.4.3. Coronary Artery Disease
14.4.4. Peripheral Artery Disease
14.4.5. Arrhythmia
14.4.6. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacy
14.5.2. Retail Pharmacy
14.5.3. Online Pharmacy
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Indication
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AstraZeneca
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co. Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Bristol-Myers Squibb Company
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Bayer AG
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Sanofi
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Boehringer Ingelheim GmbH
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. F. Hoffmann-La Roche Ltd.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Abbott Laboratories
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Gilead Sciences, Inc.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Johnson & Johnson
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Astellas Pharma, Inc.
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Eli Lilly and Company
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
15.3.15. Otsuka Holdings Co., Ltd.
15.3.15.1. Company Overview
15.3.15.2. Product Portfolio
15.3.15.3. SWOT Analysis
15.3.15.4. Financial Overview
15.3.15.5. Strategic Overview
15.3.16. Takeda Pharmaceuticals Company Ltd.
15.3.16.1. Company Overview
15.3.16.2. Product Portfolio
15.3.16.3. SWOT Analysis
15.3.16.4. Financial Overview
15.3.16.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings